Article
Genetics & Heredity
Xin Guan, Aiping Shi, Yabin Zou, Meiyang Sun, Yue Zhan, Yi Dong, Zhimin Fan
Summary: The study revealed that miR-375 plays an important role in breast cancer development, with EZH2 acting as an upstream regulator of miR-375 and FOXO1 as a downstream target mRNA. FOXO1 activates the p53 signaling pathway to suppress breast cancer progression.
FRONTIERS IN GENETICS
(2021)
Review
Oncology
Wuhan Yu, Ning Liu, Xiaogang Song, Lang Chen, Mancai Wang, Guohui Xiao, Tengfei Li, Zheyuan Wang, Youcheng Zhang
Summary: This article focuses on the value of EZH2 research in gastric cancer by examining its crucial involvement in gastric cancer progression. The article first introduces the two main functions of EZH2: histone methylation modification and DNA methylation. It then provides a detailed description of the mechanisms of EZH2 in gastric cancer-related events, and concludes with a summary of the progress in the development of EZH2 inhibitors. This review article provides researchers studying the epigenetics of gastric cancer with new research ideas to find new targets for studying the pathogenesis of gastric cancer.
Article
Biotechnology & Applied Microbiology
Liang Ai, Xiaojun Luo, Xiong Yan, Shan Jiang
Summary: The study found that miR-506-3p inhibited the progression of CRC by targeting EZH2 expression, providing a new molecular target for the clinical treatment of CRC in the future.
Article
Oncology
Mehtap Eren, Nur Kartal, Hatice Pilevneli
Summary: This study found that in p53 mutant Jurkat cells, Wip1 gene is overexpressed, leading to sensitivity to chemotherapeutic agents, and enhancing apoptotic sensitivity by attenuating DNA damage response signaling.
Article
Medicine, Research & Experimental
Xiaomin Gao, Yonghan Peng, Ziyu Fang, Ling Li, Shaoxiong Ming, Hao Dong, Rui Li, Yasheng Zhu, Wei Zhang, Baoyi Zhu, Junhao Liao, Zeyu Wang, Min Liu, Weijian Li, Jianwen Zeng, Xiaofeng Gao
Summary: Inhibition of EZH2 attenuates hyperoxaluria-induced TECs injury and reduces CaOx crystal deposition by modulating the JNK/FoxO3a pathway. EZH2 may be a promising therapeutic target in TECs injury.
Article
Cell Biology
Zhipeng Du, Mei Liu, Zhihui Wang, Zhuoying Lin, Yangyang Feng, Dean Tian, Limin Xia
Summary: KLF14 plays a critical anti-fibrotic role in liver fibrosis, and targeting the EZH2/KLF14/PPAR gamma axis may be a novel therapeutic strategy for liver fibrosis.
CELL PROLIFERATION
(2021)
Article
Oncology
Xiaxia Shao, Tao Zhao, Lei Xi, Yuhong Zhang, Jia He, Jie Zeng, Lichun Deng
Summary: The study demonstrated that the upregulation of LINC00565 and EZH2 in CRC tissues, especially in advanced stages and large tumor sizes, highlights their diagnostic value in CRC. LINC00565, predominantly located in the cytoplasm, binds with EZH2 and together they co-regulate the functions of CRC cells.
Article
Cell Biology
Li Wen, Qian Ren, Fan Guo, Xiaoyan Du, Hongliu Yang, Ping Fu, Liang Ma
Summary: Despite progress in understanding the mechanism of acute kidney injury (AKI), there are no effective drugs for treatment or prevention. This study found that the ligand-activated transcription factor aryl hydrocarbon receptor (AhR) was abnormally increased in cisplatin-induced AKI. Inhibition of AhR alleviated kidney dysfunction and tubular injury, and improved cellular senescence. Mechanistically, AhR expression was correlated with the increase of methyltransferase EZH2, and AhR inhibition suppressed EZH2 expression. The study suggests that AhR and EZH2 have mutual regulation and AhR could be a promising target for AKI treatment.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Rona Yaeger, Riccardo Mezzadra, Jenna Sinopoli, Yu Bian, Michelangelo Marasco, Esther Kaplun, Yijun Gao, HuiYong Zhao, Arnaud Da Cruz Paula, Yingjie Zhu, Almudena Chaves Perez, Kalyani Chadalavada, Edison Tse, Sudhir Chowdhry, Sydney Bowker, Qing Chang, Besnik Qeriqi, Britta Weigelt, Gouri J. Nanjangud, Michael F. Berger, Hirak Der-Torossian, Kenna Anderes, Nicholas D. Socci, Jinru Shia, Yonina R. Murciano-Goroff, Bob Li, James G. Christensen, Jorge S. Reis-Filho, David B. Solit, Elisa de Stanchina, Scott W. Lowe, Neal Rosen, Sandra Misale
Summary: Combining KRASG12C and EGFR inhibitors is an effective treatment for colorectal cancer. However, secondary resistance can reduce its efficacy. Our study found that resistance alterations preventing inhibition of ERK signaling are detected at a low frequency, except for KRASG12C amplification, which increases over time. Upon drug withdrawal, resistant cells undergo senescence, but mTOR signaling remains elevated. Targeting the senescence response may be a potential therapeutic vulnerability to overcome acquired resistance.
Article
Biochemistry & Molecular Biology
Julie Xia Zhou, Ewud Agborbesong, Linda Xiaoyan Li, Xiaogang Li
Summary: This study reveals a novel regulatory mechanism of mutant p53 through BRD4 in triple-negative breast cancer (TNBC). Inhibition of BRD4 reduces the transcription of mutant p53 and suppresses the tumorigenesis of TNBC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biotechnology & Applied Microbiology
JinShan Tang, Gang Duan, YunQing Wang, Bin Wang, WenBo Li, ZiQiang Zhu
Summary: Circular RNA_ANKIB1 modulates EZH2 through miR-26b-5p to accelerate chemoresistance in osteosarcoma.
Article
Cell Biology
Lihong Shi, Qiangsheng Zhang, Shirui Zhu, Qing Tang, Xin Chen, Rui Lan, Ningyu Wang, Yongxia Zhu
Summary: The expression of EZH2 is associated with the migration and invasion of OC cells. Inhibition of EZH2 using SKLB-03220 reduces the migration and invasion ability of OC cells by upregulating TIMP2 and downregulating MMP9.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2023)
Article
Cell Biology
Dexin Jia, Ying Xing, Yuning Zhan, Mengru Cao, Fanglin Tian, Weina Fan, Jian Huang, Yimeng Cui, Ruixue Gu, Yaowen Cui, Yuechao Liu, Shuai Zhang, Li Cai, Xiaomei Li
Summary: The study identified LINC02678 as an upregulated lncRNA in NSCLC, associated with poor prognosis in lung cancer patients. It was found to promote NSCLC progression by binding with EZH2 and enhancing cell proliferation and metastasis, suggesting its potential as a biomarker for cancer diagnosis and treatment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ji Hoon Jung, Duckgue Lee, Hyun Min Ko, Hyeung-Jin Jang
Summary: The study found that CNOT2 induces apoptosis in colorectal cancer cells by activating p53 and prolonging its half-life. CNOT2 also collaborates with MID1IP1 to promote c-Myc expression.
Article
Immunology
Chengmei He, Yanlei Yang, Zhilei Chen, Suying Liu, Taibiao Lyu, Liuting Zeng, Li Wang, Yongzhe Li, Mu Wang, Hua Chen, Fengchun Zhang
Summary: EZH2 is upregulated in CD4(+) T cells of pSS patients, promoting Tfh differentiation by enhancing STAT3 phosphorylation. EZH2 promotes Tfh differentiation and may be implicated in the pathogenesis of pSS.
FRONTIERS IN IMMUNOLOGY
(2022)